Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$443.05 1.92 (0.44%) as of 4:30 Thu 5/30


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 115.21(B)
Last Volume: 975,365 Avg Vol: 1,608,800
52 Week Range: $323.62 - $456.95
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 23,137 144,475 259,873 619,971
Total Sell Value $10,319,530 $60,539,246 $102,205,755 $209,876,745
Total People Sold 7 12 14 18
Total Sell Transactions 7 40 65 130
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 3277
  Page 14 of 132  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-04-07 4 AS $275.71 $154,935 D/D (561) 42,782 7%     
   Lee Yuchun Director   –       •      –    2022-04-07 4 AS $272.76 $549,720 D/D (2,000) 1,875 7%     
   Lee Yuchun Director   –       •      –    2022-04-07 4 OE $81.54 $163,080 D/D 2,000 3,875     -
   Lee Yuchun Director   –       •      –    2022-04-06 4 AS $267.57 $543,243 D/D (2,000) 1,875 11%     
   Lee Yuchun Director   –       •      –    2022-04-06 4 OE $81.54 $163,080 D/D 2,000 3,875     -
   Lee Yuchun Director   –       •      –    2022-04-05 4 AS $268.30 $544,993 D/D (2,000) 1,875 13%     
   Lee Yuchun Director   –       •      –    2022-04-05 4 OE $81.54 $163,080 D/D 2,000 3,875     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-04-05 4 AS $275.23 $870,552 D/D (3,163) 43,343 13%     
   Lee Yuchun Director   –       •      –    2022-04-04 4 AS $265.83 $535,431 D/D (2,000) 1,875 10%     
   Lee Yuchun Director   –       •      –    2022-04-04 4 OE $81.54 $163,080 D/D 2,000 3,875     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-04-04 4 AS $267.10 $150,452 D/D (562) 46,506 10%     
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2022-04-01 4 D $263.09 $36,043 D/D (137) 3,823     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-04-01 4 D $263.09 $353,593 D/D (1,344) 47,068     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-04-01 4 AS $261.42 $683,602 D/D (2,582) 43,620 10%     
   Mcglynn Margaret G Director   –       •      –    2022-03-31 4 AS $261.28 $1,311,346 D/D (5,000) 1,099 13%     
   Mcglynn Margaret G Director   –       •      –    2022-03-31 4 OE $127.54 $637,700 D/D 5,000 6,099     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-03-17 4 AS $250.13 $793,218 D/D (3,171) 46,202 15%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-03-17 4 AS $250.10 $708,572 D/D (2,833) 47,356 15%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-03-17 4 AS $250.06 $530,627 D/D (2,122) 48,412 15%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-25 4 AS $229.41 $1,748,990 D/D (7,572) 36,077 28%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-25 4 AS $228.88 $75,058 D/D (325) 50,189 28%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-24 4 D $227.86 $1,375,819 D/D (6,038) 43,649     -
   Arbuckle Stuart A EVP, COO   •       –      –    2022-02-24 4 D $227.86 $1,651,074 D/D (7,246) 65,066     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-02-24 4 D $227.86 $2,766,448 D/D (12,141) 89,949     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-24 4 D $227.86 $590,157 D/D (2,590) 50,514     -
  3277 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 132
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us